TradeMalta offering COVID-19 Resource Library

17th April 2020

To help companies navigate through this turbulent time, TradeMalta is building a library of resources that can provide information and insights on how to effectively respond to the challenges raised by COVID-19.

To help companies navigate through this turbulent time, TradeMalta is building a library of resources that can provide information and insights on how to effectively respond to the challenges raised by COVID-19.

TradeMalta is a public-private partnership between the Malta Chamber of Commerce, Enterprise and Industry and the Government of Malta, dedicated to helping Malta-based businesses go international.

The disruption to business is likely to continue for many months and it is critical that companies manage this crisis successfully and respond in such a way so as to build their resilience and ensure business continuity for the future to come.

Amongst the various topics covered, the resources uploaded focus primarily on crisis management, contingency planning, and resilience.

The following links include content that may provide struggling companies with strategies and ideas on how to mitigate the impact their companies are facing due to COVID-19.

Visit TradeMalta’s COVID-19 Resource Library for more content.

Free e-learning content is also available in the following link: https://www.trademalta.org/learn/  

For more information, kindly contact TradeMalta on 2247 2400 or alternatively at info@trademalta.org


FROM COVID-19

Latest News

Perit David Xuereb spoke in a vlog about the importance of recognising the changes brought about by COVID-19

17th April 2020

Almost 17,000 businesses applied for the Government wage supplement

FROM COVID-19

17th April 2020

Based on feedback received from its members, The Malta Chamber of Commerce sees the IMF projections for Malta as overly optimistic

FROM COVID-19

16th April 2020

Phase I clinical trials are planned to start in the next few months and, if successful and subject to regulatory considerations, the development required to make the vaccine available will be completed by the second half of 2021.